Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. Shares traded 13% higher ahead of the morning bell at $42.

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...

Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

The Trump administration launched TrumpRx.gov on Thursday (February 5, 2026), a website designed to help Americans purchase ...

Evommune, Inc. EVMN shares jumped Tuesday following the announcement of positive top-line results from its Phase 2a trial evaluating EVO301 for treating moderate-to-severe atopic dermatitis. The ...